TARGIT of ridicule.
Who else lives for snarky radiation debates? Settle in because nothing gets folks more riled up than the notorious TARGIT-A trial. The latest criticism focuses on the gall of the authors to compare their results with intro-op radiation (IORT) to other published results of accelerated partial breast irradiation (APBI). Because, according to this commentary, the only TARGIT-A results to be considered are the clean ones where women were randomized post-path and where local recurrence rates were 4-fold higher with IORT (4%) versus traditional whole breast radiation (1%). To really drive home their point, they conclude that a 5 Gy prescription is virtually a placebo that can’t even impact local control much less overall survival. | Polgár, Int J Radiat Oncol Biol Phys 2021